Hamilton will be responsible for guiding the company’s clinical programs, including the PICASSO 3 trial, an international, randomised, double-blinded, placebo-controlled trial of palifosfamide and doxorubicin in patients with metastatic soft tissue sarcoma.
Hamilton will report to the CEO and the chief medical officer of the company, Jonathan Lewis.
Ziopharm Oncology has also appointed J Kris Piper as the vice president of Clinical Regulatory, Quality and Project Management, who will report to Bob Morgan the senior vice president, Regulatory Affairs, Quality and Pharmaceutical Development of the company.
Both executives will be located in the company’s operational office in Boston, MA.
Lewis said that they are pleased to welcome Brian and Kris to the team at an exciting time for Ziopharm.
"Brian’s return to our senior management team comes at a time when Ziopharm is embarking on an extensive, multi-faceted, late-stage development effort with three high-value therapies," Lewis said.
"The combined insights and experience of these two individuals, which includes extensive expertise in clinical strategy, clinical operations and regulatory affairs, will contribute to the growth and positive momentum we have built at Ziopharm and will be critical as we advance our product candidates to market."